Skip to main content

Table 3 LSM change (95% CI) from baseline to weeks 4 and 12

From: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

PRO measures

Week 4

Week 12

PBO, n = 221

UPA 15 mg, n = 221

UPA 30 mg, n = 219

PBO, n = 221

UPA 15 mg, n = 221

UPA 30 mg, n = 219

PtGA (mm)

− 8.39 (− 11.69, − 5.10)

− 20.22 (− 23.57, − 16.87)***

− 25.06, (− 28.39, − 21.74)***

− 10.36 (− 13.84, − 6.88)

− 29.67 (− 33.18, − 26.16)***

− 30.51 (− 34.03, − 27.00)***

Pain VAS (mm)

− 8.84 (− 12.13, − 5.55)

− 20.86 (− 24.21, − 17.52)***

− 26.33 (− 29.65, − 23.01)***

− 10.26 (− 13.71, − 6.80)

− 29.92 (− 33.40, − 26.44)***

− 31.71 (− 35.20, − 28.22)***

HAQ-DI

− 0.22 (− 0.29, − 0.15)

− 0.43 (− 0.50, − 0.36)***

− 0.44 (− 0.51, − 0.37)***

− 0.26 (− 0.33 to − 0.18)

− 0.61 (− 0.68, − 0.53)***

− 0.55 (− 0.62, − 0.47)***

FACIT-F

2.78 (1.49, 4.06)

5.83 (4.52, 7.14)***

6.24 (4.94, 7.55)***

2.96 (1.62, 4.30)

7.91 (6.56, 9.27)***

7.74 (6.38, 9.11)***

SF-36 component scores

 PCS

2.42 (1.42, 3.42)

5.14 (4.12, 6.16)***

5.91 (4.89, 6.92)***

3.03 (1.88, 4.18)

7.58 (6.43, 8.74)***

8.01 (6.84, 9.18)***

 MCS

2.22 (1.02, 3.42)

3.43 (2.21, 4.64)

3.19 (1.98, 4.41)

2.58 (1.30, 3.87)

4.69 (3.40, 5.99)**

3.67 (2.36, 4.98)

SF-36 domainsa

 PF

2.24 (1.21, 3.26)

4.30 (3.25, 5.34)**

5.00 (3.96, 6.04)***

2.96 (1.80, 4.12)

6.92 (5.75, 8.09)***

6.81* (5.63, 8.00)***

 RP

2.30 (1.23, 3.37)

4.17 (3.08, 5.25)**

4.92 (3.84, 6.00)***

2.88 (1.69, 4.08)

6.40 (5.20, 7.61)***

6.36 (5.14, 7.58)***

 BP

3.49 (2.42, 4.56)

6.77 (5.68, 7.86)***

8.18 (7.09, 9.26)**

4.66 (3.44, 5.88)

9.44 (8.21, 10.66)***

10.38 (9.14, 11.62)***

 GH

1.78 (0.73, 2.82)

4.40 (3.33, 5.46)***

3.35 (2.29, 4.41)*

1.92 (0.78, 3.06)

5.61 (4.47, 6.76)***

5.00 (3.84, 6.15)***

 VT

2.53 (1.36, 3.69)

5.14 (3.95, 6.32)***

5.58 (4.40, 6.76)***

2.52 (1.21, 3.83)

6.77 (5.45, 8.09)***

7.05 (5.72, 8.38)***

 SF

2.30 (1.05, 3.56)

3.95 (2.67, 5.23)*

3.56 (2.29, 4.83)

2.53 (1.24, 3.82)

6.17 (4.88, 7.47)***

4.81 (3.50, 6.12)**

 RE

1.87 (0.60, 3.14)

3.56 (2.27, 4.85)*

3.32 (2.03, 4.61)

2.62 (1.31, 3.94)

5.59 (4.26, 6.91)***

4.10 (2.76, 5.44)

 MH

2.67 (1.54, 3.80)

3.61 (2.46, 4.76)

4.13 (2.99, 5.28)*

3.39 (2.14, 4.63)

4.78 (3.53, 6.03)

4.77 (3.51, 6.04)

SF-6D Utility Index

0.04 (0.02, 0.05)

0.06 (0.04, 0.07)*

0.07 (0.06, 0.09)***

0.04 (0.02, 0.05)

0.09 (0.07, 0.10)***

0.09 (0.07, 0.10)***

EQ-5D-5 L Index

0.07 (0.04, 0.10)

0.14 (0.11, 0.17)***

0.14 (0.12, 0.17)***

0.08 (0.05, 0.11)

0.19 (0.16, 0.21)***

0.18 (0.16, 0.21)***

EQ-5D VAS (mm)

4.25 (1.10, 7.39)

9.63 (6.43, 12.83)**

14.09 (10.90, 17.28)***

5.17 (1.82, 8.53)

15.86 (12.48, 19.24)***

17.19 (13.78, 20.61)***

AM joint stiffness

 Duration (min)

− 21.37 (− 40.31, − 2.43)

− 60.73 (− 79.75, − 41.71)**

− 63.06 (− 82.06, − 44.06)**

− 34.27 (− 54.63, − 13.91)

− 85.28 (− 105.61, − 64.95)***

− 85.13 (− 105.65, − 64.62)***

 Severityb

− 1.03 (− 1.35, − 0.71)

− 2.02 (− 2.35, − 1.70)***

− 2.48 (− 2.80, − 2.15)***

− 1.38 (− 1.73, − 1.03)

− 2.88 (− 3.23, − 2.53)***

− 3.26 (− 3.61, − 2.90)***

RA-WISc

− 1.70 (− 2.78, − 0.62)

− 3.08 (− 4.18, − 1.99)*

− 2.62 (− 3.80, − 1.44)

− 1.55 (− 2.69, − 0.42)

− 4.28 (− 5.41, − 3.14)***

− 3.48 (− 4.72, − 2.24)**

  1. AM morning, BP Bodily Pain, CI confidence interval, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, GH General Health, HAQ-DI Health Assessment Questionnaire-Disability Index, LSM least squares mean, MCS mental component summary, MH Mental Health, PBO placebo, PCS physical component summary, PF Physical Functioning, PRO patient-reported outcome, PtGA Patient’s Global Assessment of Disease Activity, RA-WIS Work Instability Scale for RA, RE Role-Emotional, RP Role-Physical, SD standard deviation, SF Social Functioning, SF-36 Short Form 36 Health Survey, UPA upadacitinib, VAS visual analogue scale, VT Vitality
  2. ***P < 0.001 for UPA versus PBO
  3. **P < 0.01 for UPA versus PBO
  4. *P < 0.05 for UPA versus PBO
  5. aThe baseline values and LSM changes for SF-36 domains were transformed based on the mean and standard deviation of the 1998 general US population
  6. bAssessed on a numeric scale of 1 to 10, with 10 being the worst level
  7. cCalculated only for employed patients
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us